FOI 23/139

5th March 2023

Dear

Thank you for your email.

Please note that the PL number “PLGB 12345/0002” does not correspond with any medicinal product we hold.

The current products licensed for daratumumab are:
DARZALEX 20MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION (PLGB 00242/0676)
DARZALEX 1,800 MG SOLUTION FOR INJECTION (PLGB 00242/0677).

We are grateful if you can please confirm these are the products you want us to look for this information and we can deal with this as a new request.

If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask for an internal review. Please reply to this email, within two months of this reply, specifying that you would like an Internal Review to be carried out.

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely

MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000